Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cord blood/bone marrow stem cell therapy-heart disease - Gamida Cell

Next Previous
X
Search
Drug Profile

Cord blood/bone marrow stem cell therapy-heart disease - Gamida Cell

Alternative Names: CardioCure; Cord blood stem cell therapy-myocardial infarction - Gamida-Cell; EE-AC133+; GC 011

Latest Information Update: 12 Dec 2013

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gamida-Cell
  • Class
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Myocardial infarction

Most Recent Events

  • 31 Dec 2011 No development reported - Preclinical for Myocardial infarction in Israel (unspecified route)
  • 08 Jan 2007 Data presented at the 48th Annual Meeting and Exposition of the American Society of Hematology (ASH-2006) added to the Ischaemic Heart Disease pharmacodynamics section
  • 15 Nov 2006 Preclinical development of the cardiac regeneration product is ongoing

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top